Journal of Liver

Percutaneous US-guided radiofrequency ablation of early hepatocellular carcinoma today

2^nd International Conference on Hepatology

May 09-11, 2016 Chicago, USA

Fabio Fornari

Hospital of Piacenza, Italy

Posters & Accepted Abstracts: J Liver

Abstract:

Hepatocellular carcinoma (HCC) is the fifth most common malignancy cancer worldwide and the third most common cause of cancer mortality. Local ablation is considered the first line treatment option for patients at very early or early stage (BCLC 0 and A) not suitable for surgical therapies. Radiofrequency ablation (RFA) has a higher anticancer effect than percutaneous ethanol injection (PEI), leading to a better local control of the disease. Recently we have demonstrated a higher cumulative and local recurrences rates in patients with single HCC smaller than 2 cm treated with PEI. An open question is whether RFA can compete with surgical resection as a first-line treatment for patients with small (<4-5 cm in diameter) and solitary HCC. In 605 HCC patients, BCLC 0 and A, there was no significant difference in overall survival (OS) between surgical resection (SR) and RFA. Also in the study of Kim et al., RFA provides comparable OS versus SR although RFA carries a higher risk of recurrence. In a database constructed on a Japanese nationwide survey, Hasegawa et al., showed that SR results in longer OS than RFA in patients with HCC. In our multicenter Italian survey comparing SR and RFA in 544 CPT A cirrhotic patients with single <3 cm HCC, showed that RFA can provide results comparable to SR. In a more recent meta-analysis of RCTs and non-RCTs comparing RFA and SR for small HCC Wang et al., concluded that the effectiveness of RFA is comparable to SR with fewer complications but higher recurrence.

Biography :

Email: f.fornari@ausl.pc.it